SCHEMBL3884841

SCHEMBL3884841

Cc1ccc(NC(=O)c2cccc(CNS(=O)(=O)c3ccc(-c4ccccc4)cc3)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 1/20 0.68
GPR55 Q9Y2T6 2/20 0.64
CYP19A1 P11511 1/20 0.58
CA12 O43570 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
ATM Q13315 1/20 0.56
CA9 Q16790 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MMP9 P14780 1/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 2/20 0.56
NOS2 P35228 1/20 0.55
POLB P06746 2/20 0.55
RECQL P46063 1/20 0.55
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
TDP1 Q9NUW8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3882407 0.86 GPR17 (0.64) GPR17CYP19A1L3MBTL1LMNAMAPT
SCHEMBL3883213 0.84 CYP19A1 (0.57) GPR17GPR55CYP19A1CA12CYP1A2
SCHEMBL3875842 0.82 HTT (0.75) GPR55LMNAPOLBALDH1A1SMN1; SMN2
SCHEMBL27450611 0.81 CYP19A1 (0.74) GPR17CYP19A1CA12CYP1A2CYP3A4
SCHEMBL3873636 0.81 CYP19A1 (0.59) GPR55CYP19A1CA12CYP1A2CYP3A4
SCHEMBL31224707 0.80 MAPT (0.64) GPR17GPR55CYP19A1LMNAMAPT
SCHEMBL3874748 0.80 NAMPT (0.60) GPR55CYP19A1CA12CA9LMNA
SCHEMBL3872637 0.79 CYP19A1 (0.56) GPR55CYP19A1CA12CYP1A2CYP3A4
SCHEMBL3873119 0.77 HTT (0.67) GPR55LMNAPOLBALDH1A1
SCHEMBL29019313 0.77 CA12 (0.82) GPR55CYP19A1CA12CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 GPR17 3455/4885GPR55 2780/4885CYP19A1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.